H
Haimai Medical
Regenerative medical technology for cardiovascular disease surgeries
About Haimai Medical
Haimai Medical, founded in Suzhou, China, in 2021, is a developer of tissue engineering and regenerative medical technologies for cardiovascular disease surgeries. The company focuses on creating solutions that promote tissue repair and regeneration. These include allogeneic small-caliber tissue-engineered blood vessels intended for various applications such as vascular access for chronic renal failure dialysis, blood vessel replacement for lower extremity arterial trauma, and for treating lower extremity atherosclerosis and coronary heart disease bypass surgery.
The company secured its first funding in a Series A round in August 2024, led by IDG Capital. While the exact amount was undisclosed, this investment supports the company's research and development efforts in a competitive landscape.
Haimai Medical aims to provide advanced materials that can offer long-term durability for valve replacements and other cardiovascular procedures. Its product offerings are designed to address the challenges in treating complex cardiovascular conditions by providing alternatives for tissue and vessel repair.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Suzhou Shi, China
- Open positions
- None listed
- Dealroom signal
- 20.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, medical implants, Surgery, Cardiology and cardiovascular, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2026 | — | — | Suzhou Capital Group · BOC International | ↗ |
| SERIES A✓Equity / VC | Dec 2025 | $14M | $55M | SHC Shanghai Biomedical Fund · Silicon Valley · Puhua Capital · IDG Capital | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- BIBeijing Huafang Investment
Series A7 investors entered at this stage
- PCPuhua Capital
SHC Shanghai Biomedical Fund- SVSilicon Valley
IDG Capital
Suzhou International Development Venture Capital Holding
BOC International- SGSuzhou Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Haimai Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Haimai Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.